On September 27, 2023 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, reported that an abstract highlighting pre-clinical data on its CRB-601 anti-aVb8 integrin monoclonal antibody has been accepted for presentation as a poster at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), to be in San Diego, CA November 1-5, 2023 (Press release, Corbus Pharmaceuticals, SEP 27, 2023, View Source [SID1234635474]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Details

Abstract Number:

1388

Title:

CRB-601, an integrin αvβ8 blocking antibody entering Phase I: pre-clinical and translational biomarkers for indication selection.

Authors:

Vaishali Shinde, Daqing Wang, Danish Memon, Maneesh Singh, James Rindone, Rodney Carter, B.S, Naomi Muse, MBA, Ian Hodgson, PhD, Andrew Kolodziej and Rachael Brake.

Session Date:

Saturday November 4

Presentation Time:

9:00am to 8:30pm PT

CRB-601 is a potent and selective integrin αvβ8 blocking monoclonal antibody that can overcome tumor immune exclusion and enhance the activity of immune checkpoint inhibitors in vivo. The IND submission for CRB-601 is anticipated in Q4 2023, and the Company expects to enroll the first patient in its Phase 1 study in the first half of 2024.

The CRB-601 abstract will be available on the SITC (Free SITC Whitepaper) website as of Oct. 31, 2023, and the poster will be made available on the Company website following the presenation.